Scientific Foundation
Clinical discussions are informed by cellular biology, mechanisms of action, published literature and the recognised limitations of current evidence.
For Physicians
Advancing regenerative medicine through science and clinical collaboration.
CELLMEX supports physicians with access to cellular and cell-free regenerative technologies, scientific information, laboratory consultation, patient-referral coordination and indication-specific clinical review.
Physician-to-Physician Collaboration
A clinically responsible approach to regenerative medicine
CELLMEX has been developed to support physicians interested in evaluating or incorporating regenerative medicine within a structured, scientifically informed clinical framework.
Our platform extends beyond a single cellular product. It includes mesenchymal stromal cells, extracellular-vesicle technologies, secretome and conditioned-media preparations, tissue-directed cellular research and selected immune-cell platforms.
Every patient requires individual medical assessment. Treatment planning should consider the diagnosis, disease severity, prior interventions, current medication, relevant imaging, laboratory results, risk profile and available alternatives.
CELLMEX is intended to function as a clinical, scientific and laboratory partner. The referring or treating physician remains central to patient care.
Why Physicians Work with CELLMEX
Scientific support beyond product supply
Laboratory Support
CELLMEX provides access to laboratory-based knowledge involving cellular culture, handling, preservation, cell-derived preparations and current in-vitro and ex-vivo research.
Multiple Biological Platforms
Physicians may request information concerning MSCs, purified exosomes, small extracellular vesicles, secretome, conditioned media, differentiated MSCs and selected immune-cell technologies.
Evidence-Based Philosophy
Biological plausibility is not treated as proof of efficacy. Clinical positioning considers evidence quality, product identity, manufacturing and patient-specific risk.
Regional and International Collaboration
CELLMEX supports physician enquiries, patient referrals and collaborative discussions across Mexico, Latin America and international markets.
Individualised Clinical Planning
Treatment decisions are based on the patient's diagnosis, objectives, prior therapies, medical history, clinical status and relevant testing.
Clinical Areas of Interest
Areas in which physicians may request scientific or clinical review
Inclusion below does not mean that a regenerative treatment is established or appropriate for every diagnosis within that specialty.
Orthopaedics
Sports Medicine
Rheumatology
Neurology
Pain Medicine
Spine Disorders
Autoimmune Disease
Wound Care
Dermatology
Aesthetic Medicine
Endocrinology
Research Programmes
Regenerative Medicine Platform
Cellular, cell-free and immune-based technologies
Each platform has distinct manufacturing, characterisation, safety and clinical considerations.
Mesenchymal Stromal Cells
MSC platforms are investigated for immunomodulatory, anti-inflammatory, trophic and tissue-supporting biological activity.
- Cell source and donor considerations
- Culture and passage characteristics
- Viability and identity
- Route and administration planning
- Indication-specific evidence review
Exosomes, EVs and Secretome
Cell-free platforms include purified or enriched extracellular-vesicle fractions, MSC secretome, conditioned media and exosome-depleted preparations.
- Product identity and terminology
- Isolation and purification method
- Particle and protein characterisation
- Soluble and vesicular composition
- Potency and clinical-evidence limitations
Differentiated and Tissue-Directed MSCs
Controlled differentiation or lineage-associated development seeks to influence cellular phenotype for specific research or translational objectives.
- Differentiation protocols
- Phenotype confirmation
- Functional assessment
- Stability and safety considerations
- Investigational positioning
Immune Cell Therapies
Immune-cell platforms may involve the isolation, activation, expansion or modification of selected immune-cell populations.
- Cell identity and purity
- Activation and functional state
- Potency and safety testing
- Indication-specific clinical rationale
- Research and regulatory requirements
Clinical Protocol Library
Request physician and clinical-support documentation
Available documents depend on the technology, indication, intended use and professional credentials of the requesting physician.
Clinical Treatment Protocols
Physician-use protocols outlining patient assessment, preparation, administration, monitoring and follow-up considerations.
Patient Eligibility Guidelines
Clinical factors that may support, limit or contraindicate further evaluation for a specific regenerative intervention.
Administration Guidance
Product-specific handling, preparation, administration-route and clinical-observation information where available.
Scientific Literature Reviews
Selected peer-reviewed publications and evidence summaries relevant to a technology or proposed clinical application.
Informed Consent Templates
Draft consent materials describing the proposed intervention, alternatives, uncertainties, potential risks and follow-up responsibilities.
Follow-Up and Outcome Templates
Suggested documentation for clinical monitoring, adverse-event reporting, symptom review and outcome assessment.
Product and Laboratory Information
Available technical information regarding product identity, biological source, handling, storage and relevant quality documentation.
White Papers and Technical Reports
Scientific documents discussing mechanisms, manufacturing, characterisation, evidence and responsible clinical translation.
Patient Referral Process
A structured pathway for physician-referred patients
Submit Clinical Summary
The referring physician provides the diagnosis, treatment history, current condition and reason for referral.
Medical Record Review
Relevant reports, laboratory results, imaging and previous treatment information are reviewed.
Clinical Consultation
CELLMEX discusses the case with the referring physician and may arrange further patient evaluation.
Clinical Recommendation
The physician receives a proposed pathway, limitations, alternatives and follow-up considerations.
Treatment and Follow-Up
Where treatment is appropriate, scheduling, documentation and follow-up communication are coordinated.
Ordering and Product Information
Request information before placing an order
Product availability, supply terms and clinical documentation may vary by jurisdiction, technology and intended use.
Physicians may request information regarding:
- Available cellular and cell-free platforms
- Product identity and biological source
- Presentation and available concentration
- Storage and handling requirements
- Temperature-controlled shipping
- Administration and monitoring documentation
- Clinical literature and technical information
- Pricing and quotation terms
- Regulatory and import considerations
- Minimum ordering or scheduling requirements
Physician FAQs
Common clinical and professional questions
How do I refer a patient?
Submit a brief clinical summary through the Medical
Affairs form. Include the diagnosis, current
condition, previous treatment, relevant imaging or
laboratory findings and the reason for referral.
Who determines patient eligibility?
Eligibility is determined following physician-led
medical review. The referring physician may
participate in the discussion, but no patient is
accepted solely on the basis of an administrative
enquiry.
Can I request scientific publications?
Yes. Physicians may request peer-reviewed
literature, evidence summaries and technical
references relevant to a CELLMEX technology or
proposed clinical application.
Can protocols be customised?
Protocols may require patient-specific adaptation
based on diagnosis, severity, comorbidities,
medications, previous treatment and clinical risk.
Any modification must remain medically and
scientifically justified.
Can CELLMEX work with my existing treatment plan?
Yes. Where clinically appropriate, CELLMEX may
evaluate how a proposed regenerative intervention
could be coordinated with the patient's existing
specialist care and standard treatment.
Do you support international physicians?
Yes. CELLMEX may support international physician
referrals, scientific consultations, medical-record
review and treatment coordination, subject to
jurisdictional and regulatory considerations.
Can we establish a research collaboration?
Research discussions may involve in-vitro or
ex-vivo studies, laboratory methods, product
characterisation, clinical observation programmes
or preparation of formal research proposals.
How do I request a laboratory consultation?
Select Laboratory Consultation in the Medical
Affairs enquiry form and briefly describe the
technology, research objective or clinical question
requiring review.
Scientific and Clinical Qualification
Responsible interpretation remains essential
Important professional notice
A biological mechanism, laboratory result or published case series does not by itself establish clinical efficacy.
Results obtained using one cellular or cell-free preparation cannot automatically be attributed to another product with a different source, manufacturing process, formulation or route of administration.
Clinical use must consider applicable law, professional scope of practice, patient-specific risk, informed consent, quality documentation and the available level of evidence.
Medical Affairs
Request protocols, refer a patient or submit a professional enquiry
Provide your professional information and select the type of clinical, scientific or ordering support required.
Medical Affairs Email
medicalaffairs@cellmex.com
Professional Telephone
+52 (000) 000 0000
Office Hours
Monday–Friday
9:00 a.m.–5:00 p.m.
Mexico Central Time
Professional Enquiries
Protocols · Referrals · Ordering · Research · Laboratory Consultation